Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. More Details
No risks detected for BOUL from our risk checks.
Adequate balance sheet with reasonable growth potential.
Share Price & News
How has Boule Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BOUL has not had significant price volatility in the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned 24% over the past year.
Return vs Market: BOUL underperformed the Swedish Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Boule Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StIs Boule Diagnostics (STO:BOUL) A Risky Investment?
2 weeks ago | Simply Wall StDo Institutions Own Boule Diagnostics AB (publ) (STO:BOUL) Shares?
1 month ago | Simply Wall StThe President of Boule Diagnostics AB (publ) (STO:BOUL), Jesper Söderqvist, Just Bought 30% More Shares
Is Boule Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BOUL (SEK56.4) is trading below our estimate of fair value (SEK89.44)
Significantly Below Fair Value: BOUL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BOUL is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: BOUL is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BOUL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BOUL is good value based on its PB Ratio (3.7x) compared to the SE Medical Equipment industry average (5.3x).
How is Boule Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOUL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: BOUL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BOUL's is expected to become profitable in the next 3 years.
Revenue vs Market: BOUL's revenue (9.6% per year) is forecast to grow faster than the Swedish market (3% per year).
High Growth Revenue: BOUL's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BOUL's Return on Equity is forecast to be low in 3 years time (17.3%).
How has Boule Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOUL is currently unprofitable.
Growing Profit Margin: BOUL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BOUL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare BOUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOUL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).
Return on Equity
High ROE: BOUL has a negative Return on Equity (-2.74%), as it is currently unprofitable.
How is Boule Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: BOUL's short term assets (SEK235.9M) exceed its short term liabilities (SEK169.8M).
Long Term Liabilities: BOUL's short term assets (SEK235.9M) exceed its long term liabilities (SEK97.6M).
Debt to Equity History and Analysis
Debt Level: BOUL's debt to equity ratio (39.4%) is considered satisfactory.
Reducing Debt: BOUL's debt to equity ratio has increased from 26.3% to 39.4% over the past 5 years.
Debt Coverage: BOUL's debt is well covered by operating cash flow (64.7%).
Interest Coverage: BOUL is unprofitable, therefore interest payments are not well covered by earnings.
What is Boule Diagnostics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BOUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BOUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BOUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BOUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: BOUL is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BOUL's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesper Söderqvist (54 yo)
Mr. Jesper Söderqvist, Ph.D., serves as Director at Arcoma AB since June 2020 and Board Member and Chief Executive Officer of Dekatria AB. He served as Chief Executive Officer of Arcoma AB until June 2020. ...
|President||0.42yr||no data||0.077% |
|Chief Financial Officer||3yrs||no data||0.027% |
|Human Resources Director||2.75yrs||no data||0.0027% |
|Head of Marketing||16.75yrs||no data||no data|
|Head of Development - Reagents & Consumables||28.75yrs||no data||no data|
|Head of Development - Instruments & Systems||13.75yrs||no data||no data|
|Senior Vice President of R&D OEM - CDS||no data||no data||0.43% |
|Senior Vice President of Quality & Regulatory||3.75yrs||no data||no data|
|Senior Vice President of Commercial Operations||2.58yrs||no data||0.010% |
|Senior Vice President of Instrument Production||0.67yr||no data||no data|
|Senior VP of Production of Consumables||no data||no data||no data|
|Sales & Marketing Director for US||no data||no data||no data|
Experienced Management: BOUL's management team is considered experienced (3 years average tenure).
|Independent Director||4.75yrs||kr235.00k||0.046% |
|Independent Chairman of the Board||4.75yrs||kr470.00k||0.46% |
|Independent Director||6.75yrs||kr235.00k||10.08% |
|Independent Director||2.75yrs||kr235.00k||no data|
|Independent Director||5.75yrs||kr235.00k||0.055% |
Experienced Board: BOUL's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BOUL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boule Diagnostics AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Boule Diagnostics AB (publ)
- Ticker: BOUL
- Exchange: OM
- Founded: 1956
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr1.116b
- Shares outstanding: 19.42m
- Website: https://www.boule.com
Number of Employees
- Boule Diagnostics AB (publ)
- Domnarvsgatan 4
- Stockholm County
- 163 53
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BOUL||OM (OMX Nordic Exchange Stockholm)||Yes||Common Shares||SE||SEK||Jun 2011|
|0P4Z||LSE (London Stock Exchange)||Yes||Common Shares||GB||SEK||Jun 2011|
|BDAB.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jun 2011|
|BOULS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||SEK||Jun 2011|
|8BD||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Jun 2011|
Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 20:51|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.